AstraZeneca share price logo

AstraZeneca

NYSE: AZN

$162.70

-2.07

(-1.26%)

as on

AstraZeneca Stock Performance

as on September 5, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $161.13
    $163.78
    downward going graph

    0.96%

    Downside

    0.66%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $145.79
    $212.71
    downward going graph

    10.39%

    Downside

    30.74%

    Upside

    downward going graph

AstraZeneca share price movements today

Previous Close
$164.77
Open
$162.90
Volume
1.8M
Market Cap
$250.2B
Dividend Yield
129.31%
Day's Low - High
$161.13 - $163.78
52 Week Low - High
$145.79 - $212.71

AstraZeneca Historical Returns

1 Month Return
+ 5.88 %
3 Month Return
-9.37 %
1 Year Return
+ 0.74 %
3 Year Return
+ 20.91 %
5 Year Return
+ 40.04 %

AstraZeneca Stock Fundamentals & Key Indicators

Check AstraZeneca market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$250.2B

EPS (TTM)

10.0533

Dividend Yield

129.31%

Quarterly Earnings Growth YOY

0.03%

PE Ratio (TTM)

24.34

Industry PE ratio

22.90

PEG Ratio

1.259

EBITDA

19.9B

Revenue (TTM)

61.4B

Profit Margin

17.02%

Return On Equity TTM

21.97%

AstraZeneca Stock Valuation

Track how AstraZeneca P/E has moved over time to understand its valuation trends.

AstraZeneca in the last 5 years

  • Overview

  • Trends

Lowest (33.41x)

March 31, 2025

Industry (22.90x)

September 4, 2026

Today (24.34x)

September 4, 2026

Highest (58.97x)

March 31, 2026

LowHigh

Today’s Price to Earnings Ratio: 24.34x

AstraZeneca vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of AstraZeneca with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
AstraZeneca image
AstraZeneca
BUY$250.2B40.04%24.3417.02%129.31%
Eli Lilly & Co image
Eli Lilly & Co
BUY$1.1T346.81%38.8484.01%0.58%
AbbVie image
AbbVie
BUY$459.4B133.12%70.6871.48%2.7199999999999998%
Johnson & Johnson image
Johnson & Johnson
BUY$653.5B59.07%32.1970.45%1.9%
Merck & Company image
Merck & Company
BUY$369.7B97.18%120.354.77%221.58%

Stock Returns calculator for AstraZeneca Stock including INR - Dollar returns

The AstraZeneca stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

AstraZeneca investment value today

Current value as on today

₹1,06,585

Returns

₹6,585

(+6.58%)

Returns from AstraZeneca Stock

-₹526 (-0.53%)

Dollar Impact

₹7,110 (+7.11%)

Analyst Recommendation on AstraZeneca Stock

Based on 16 analysts

BUY

87.50%

Buy

6.25%

Hold

6.25%

Sell

Based on 16 analysts, 87.5% of analysts recommend a 'BUY' rating for AstraZeneca. Average target price of $212.54

AstraZeneca Share Price Target

Get share price movements and forecasts by analysts on AstraZeneca.

What analysts predicted

23.45%UPSIDE

Target Price

$212.54

Current Price

$162.7

Analyzed by

16 Analysts

Target

$212.54

AstraZeneca target price $212.54, a slight upside of 23.45% compared to current price of $162.7. According to 16 analysts rating.

Indian Investors' Interest in AstraZeneca Stock

Investment in AstraZeneca Shares on INDmoney has dropped by -25.33% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-25.33% versus previous 30 day period

Search interest for AstraZeneca Stock has increased by 60% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:60% versus previous 30 day period

AstraZeneca Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
12,679
12,938
13,565
14,891
13,588
14,457
15,191
15,503
15,288
15,384
Gross Profit
10,461
10,755
10,484
12,166
11,347
11,984
12,390
12,385
12,610
12,861
Operating Income
3,115
2,746
2,106
2,036
3,674
3,508
3,583
2,978
4,246
3,164
EBITDA
4,468
4,119
4,102
2,809
5,035
4,955
5,227
4,612
5,673
5,163
Interest Expense
413
443
457
429
349
439
434
472
393
435
Depreciation
-
-
1,817
714
1,284
1,389
1,549
1,511
1,366
1,929
Income Before Tax
2,800
2,397
1,828
1,666
3,402
3,127
3,244
2,629
3,914
2,799
Income Tax Expense
620
469
395
166
481
679
709
300
833
291
Net Income
2,179
1,927
1,429
1,500
2,916
2,450
2,533
2,326
3,080
2,507
Net Profit Margin
17.19%
14.89%
10.53%
10.07%
21.46%
16.95%
16.67%
15.00%
20.15%
16.30%

AstraZeneca Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
23,002
22,465
22,090
24,384
26,617
37,417
44,351
45,811
54,073
58,739
Gross Profit
18,876
18,147
17,154
19,463
21,318
24,980
31,960
37,543
43,866
48,106
Operating Income
4,902
3,677
3,387
2,924
5,162
1,056
3,757
8,193
10,003
13,743
EBITDA
7,276
6,623
7,112
6,712
8,084
5,113
9,085
13,422
15,438
19,829
Interest Expense
1,367
1,360
1,366
1,402
1,272
1,276
1,330
1,589
1,682
1,694
Depreciation
-
-
-
-
-
4,102
5,254
4,934
5,065
5,733
Income Before Tax
3,552
2,227
1,993
1,548
3,916
-265
2,501
6,899
8,691
12,402
Income Tax Expense
146
-641
-57
321
772
-380
-792
938
1,650
2,169
Net Income
3,499
3,001
2,155
1,335
3,196
112
3,288
5,955
7,035
10,255
Net Profit Margin
15.21%
13.36%
9.76%
5.47%
12.01%
0.30%
7.41%
13.00%
13.01%
17.46%

AstraZeneca Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
2,397
1,828
1,666
2,916
3,127
2,533
2,356
3,914
2,476
Operating Cash Flow
3,085
3,383
2,907
3,713
3,386
5,134
2,430
3,359
2,887
Investing Cash Flow
-2,872
-1,514
-1,181
-1,253
-2,108
-2,001
-1,521
-1,792
-2,931
Financing Cash Flow
-1,222
-4,131
-671
-2,707
518
-2,078
-3,356
267
-2,554
Change in Cash
-1,015
-2,242
994
-222
1,825
1,048
-2,410
1,816
-2,691

AstraZeneca Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2,227
1,993
1,548
3,916
-265
2,501
6,899
8,691
10,225
Operating Cash Flow
3,578
2,618
2,969
4,799
5,963
9,808
10,345
11,861
14,575
Investing Cash Flow
-2,328
963
-657
-285
-11,058
-2,960
-4,064
-7,980
-6,808
Financing Cash Flow
-2,936
-2,044
-1,765
-2,203
3,649
-6,823
-6,567
-3,996
-7,544
Change in Cash
-1,752
1,499
552
2,323
-1,508
-55
-346
-208
269

Mutual Funds that own AstraZeneca Stock

Check out the Mutual Funds with significant holdings in AstraZeneca.

Funds
Holdings
Shares Held
VANGUARD STAR FUNDS
1.414373%
21937551
New Perspective Fund
1.019868%
15818602
VANGUARD TAX-MANAGED FUNDS
0.935153%
14504632
VANGUARD CHESTER FUNDS
0.775082%
12021874
EUPAC Fund
0.667271%
10349667
See all

Global Institutional Holdings in AstraZeneca

Funds
Holdings
iShares
5.04%
Vanguard
2.27%
UBS
1.36%
Theofanis Kolokotrones
1.17%
Ken Fisher
0.72%
See all

AstraZeneca News & Key Events

  • img

    Today's Timeline - 03 September

    Thu, 10:00 PM

    -

    AstraZeneca's CARDIO-TTRansform study completes, signaling potential positive outcomes for eplontersen in treating rare heart disease.

    Thu, 10:00 PM

    -

    AstraZeneca's AI pathology study completes, reinforcing its innovation in cancer diagnostics and potential growth in oncology.

    Thu, 10:00 PM

    -

    AstraZeneca halts early ceralasertib study, indicating a shift in priorities for its oncology pipeline.

Insights on AstraZeneca

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    AstraZeneca PLC has seen steady revenue growth over the last two quarters, increasing from $15.28 billion to $15.38 billion. This reflects an average revenue increase of 0.6% per quarter.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 77.5% return, outperforming this stock by 77.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly & Co. has given 41.2% return, outperforming this stock by 19.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    AstraZeneca PLC has experienced a decline in net profit for the last two quarters. The profits fell from $3.08 billion to $2.50 billion, showing an average decrease of 18.6% per quarter.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, AZN stock has moved down by -12.5%

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
OrganisationAstraZeneca
Headquarters1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
IndustryDrug Manufacturers - General
CEOMr. Pascal Claude Roland Soriot D.V.M., M.B.A.
E-voting on sharesClick here to vote

Key Management of AstraZeneca

Name

Title

Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.

CEO & Executive Director

Dr. Aradhana Sarin M.D.

CFO & Executive Director

Mr. Joris Silon

Head of Investor Relations

Dr. Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology R&D

Mr. David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

Ms. Ruth March FMEDSCI, O.B.E., Ph.D.

Senior VP of Precision Medicine - R&D Oncology

Ms. Pam P. Cheng

EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Mr. Jeffrey Pott J.D.

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

Dr. Ruud Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Ms. Iskra Reic

Executive Vice President of International

FAQs

What is AstraZeneca share price today?

AstraZeneca share price today is $162.70 as on at the close of the market. AstraZeneca share today touched a day high of $163.78 and a low of $161.13.

What is the 52 week high and 52 week low for AstraZeneca share?

AstraZeneca share touched a 52 week high of $212.71 on and a 52 week low of $145.79 on . AstraZeneca stock price today i.e. is closed at $162.70,which is 23.51% down from its 52 week high and 11.60% up from its 52 week low.

What is AstraZeneca's market capitalisation today?

AstraZeneca market capitalisation is $0.25T as on .

How to invest in AstraZeneca Stock (AZN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for AstraZeneca on INDmoney app. Click on Buy button. You can invest as low as $1.5 in AstraZeneca Shares that will get you 0.0092 shares as per AstraZeneca share price of $162.70 per share as on September 5, 2026 at 8:46 am IST.

What is the minimum amount required to buy AstraZeneca Stock (AZN) from India?

Indian investors can start investing in AstraZeneca (AZN) shares with as little as ₹94.49 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.90 in AstraZeneca stock (as per the Rupee-Dollar exchange rate as on ). Based on AstraZeneca share’s latest price of $162.70 as on September 5, 2026 at 8:46 am IST, you will get 0.0615 shares of AstraZeneca. Learn more about fractional shares .

What are the returns that AstraZeneca has given to Indian investors in the last 5 years?

AstraZeneca stock has given 40.04% share price returns and 29.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?